BioMarin Pharmaceutical Inc.（BMRN）股票分析BMRNBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BioMarin Pharmaceutical Inc appears to be a good buy at the current price of $64.665, especially considering its strong revenue growth, with Q2 2026 revenue reported at $989.7 million, a 20% increase year-over-year. Additionally, the forward P/E ratio of 13.23 suggests the stock is undervalued compared to its earnings potential. The main risk is the recent increase in debt to equity, which rose to 66.22% in Q2 2026, indicating potential financial strain.

24 analysts cover BMRN: 19 rate it Buy, 5 Hold and 0 Sell. The average price target is 87.35.